Kristi Rosa

Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

Targeting PIK3CA With Allosteric Inhibitors Is Promising New Approach in Breast Cancer

December 6th 2024

Felipe Batalini, MD, details how targeting PIK3CA is evolving in breast cancer as new allosteric inhibitors have emerged and showed promising safety/efficacy.

Chemotherapy-Free Regimen Shows Promise in HER2+/HR+ Metastatic Breast Cancer

December 5th 2024

DETECT V trial data suggest dual HER2-targeted and endocrine therapy might be an effective option in HER2+/HR+ breast cancer.

TRANSCEND CLL 004 Analysis Proposes Meaningful Change Thresholds for PRO Measures in R/R CLL

December 4th 2024

Meaningful thresholds for interpreting changes in 3 EORTC QLQ-CLL17 domain scores have been identified in a PRO analysis of the TRANSCEND CLL 004 trial.

Disitamab Vedotin Shows Early Efficacy in HER2-Expressing Breast Cancer With PAM Pathway Abnormalities

December 4th 2024

Disitamab vedotin showed early activity in HER2-expressing metastatic breast cancer with abnormal PAM pathway activation.

FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan for EGFR+ NSCLC

December 3rd 2024

Sacituzumab tirumotecan has received breakthrough therapy designation from the FDA for use in select patients with EGFR+ non–small cell lung cancer.

NMPA Grants Conditional Approval to Fruquintinib Plus Sintilimab for pMMR Endometrial Cancer

December 3rd 2024

Fruquintinib plus sintilimab injection has received conditional approval from the NMPA for mismatch repair–proficient advanced endometrial cancer.

FDA Awards Fast Track Designation to LBS-007 for Acute Myeloid Leukemia

December 3rd 2024

LBS-007 receives fast track status from the FDA for use in patients with acute myeloid leukemia.

OncLive’s November Roundup of Key FDA Approvals in Oncology

December 3rd 2024

Here is your snapshot of all treatment options that the FDA cleared in November 2024 spanning tumor types.

Vorasidenib Shows Consistent Efficacy With Manageable Safety in IDH1/2-Mutant Diffuse Glioma

November 23rd 2024

Updated INDIGO data reveal that vorasidenib continues to showcase improved efficacy over placebo in patients with IDH1/2-mutated diffuse glioma.

NanO2 Plus Radiation/Temozolomide Is Under Exploration in Newly Diagnosed Glioblastoma

November 23rd 2024

Early safety findings from the phase 2b RESTORE study (NCT03862430) of NanO2 plus radiation and temozolomide in newly diagnosed glioblastoma were shared.

IGV-001 Showcases Positive Benefit-Risk Profile in Newly Diagnosed Glioblastoma

November 22nd 2024

IGV-001, an autologous cell immunotherapy, demonstrated an acceptable safety profile in patients with newly diagnosed glioblastoma.

Osimertinib Approaches EU Approval in Locally Advanced EGFR+ NSCLC After Chemoradiation

November 20th 2024

Osimertinib has been recommended for approval in patients with locally advanced, unresectable, EGFR-mutant NSCLC after chemoradiation.

Lisaftoclax NDA Accepted for Review in China for Relapsed/Refractory CLL/SLL

November 20th 2024

An NDA for lisaftoclax in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma has been accepted for review.

Retrospective Data Show BTK Inhibitors May Be Optimal Second-Line Approach in Late-Relapse Mantle Cell Lymphoma

November 19th 2024

Second-line BTK inhibitors were associated with improved PFS2 and OS2 in late-relapsed mantle cell lymphoma.

Toripalimab Plus Chemo Approved in UK for Frontline Nasopharyngeal Carcinoma and ESCC

November 18th 2024

The UK MHRA approved frontline toripalimab plus chemotherapy for recurrent/metastatic NPC, as well as for advanced, recurrent, or metastatic ESCC.

Amivantamab/Lazertinib Combo Approaches EU Approval in EGFR+ Advanced NSCLC

November 18th 2024

The EMA’s CHMP has issued a positive opinion regarding the use of amivantamab plus lazertinib in select patients with EGFR+ non–small cell lung cancer.

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

November 15th 2024

The FDA has approved revumenib (Revuforj) for the treatment of adult and pediatric patients aged 1 year and older with relapsed or refractory acute leukemia and a KMT2A translocation.

Dr Dimopoulos on Efficacy Findings From the DREAMM-8 Trial in Multiple Myeloma

November 9th 2024

Meletios Dimopoulos, MD, discusses the design of and findings from the DREAMM-8 trial investigating BPd in patients with multiple myeloma.

Dr Singer on the Efficacy of IO/TKI Doublets in Advanced RCC

November 9th 2024

Adam E. Singer, MD, PhD, discusses currently available combination treatment regimens for the first-line treatment of patients with renal cell carcinoma.

OncLive’s October Roundup of Key FDA Approvals in Oncology

November 5th 2024

Here is your snapshot of all therapeutic options that the FDA approved in October 2024 spanning tumor types.